India Tightens Ebola Surveillance As Rare Vaccine-Less Strain Sparks Global Alarm

India has stepped up surveillance at airports and seaports and begun reviewing quarantine, isolation, and laboratory preparedness measures following growing international concern over the rapidly spreading Ebola outbreak in parts of Africa, where health authorities are grappling with a rare strain of the virus for which no approved vaccine or targeted treatment currently exists.

The heightened alert has already begun affecting diplomatic engagements and international movement, with the fourth India-Africa Forum Summit postponed indefinitely amid concerns over the worsening outbreak in parts of the African continent.

The latest outbreak, centred in the eastern regions of the Democratic Republic of the Congo (DRC) and extending into neighbouring Uganda, was recently declared a “public health emergency of international concern” by the World Health Organization (WHO) after cases spread across provinces and international borders.

WHO Director-General Tedros Adhanom Ghebreyesus had recently expressed deep concern over “the scale and speed of the epidemic”, warning that both suspected infections and deaths were likely to increase further as surveillance and laboratory detection improved.

According to current estimates, more than 600 suspected cases and over 130 deaths have already been linked to the outbreak, although the number of laboratory-confirmed infections remains lower because of delayed diagnosis, weak healthcare infrastructure, and logistical challenges in conflict-hit regions. Public health experts warn that population movement across porous borders in eastern Africa could facilitate wider transmission.

What has particularly alarmed scientists is that the outbreak involves the rare Bundibugyo strain of the Ebola virus — a species for which no licensed vaccine or approved antiviral therapy currently exists.

While vaccines developed against the Zaire strain helped contain previous Ebola outbreaks in Africa, experts say the present outbreak poses a more complex challenge because Bundibugyo has caused only two documented outbreaks previously — one in Uganda in 2007 and another in Congo in 2012. The limited historical experience has left global health systems with far fewer medical countermeasures.

WHO officials have indicated that two experimental vaccine candidates are under development, but neither has completed clinical trials. Scientists estimate that even under accelerated conditions, an effective vaccine may still take six to nine months before wider deployment becomes possible.

The absence of an immediately deployable vaccine has intensified global concern because Ebola remains one of the world’s deadliest viral diseases, with mortality rates during earlier outbreaks ranging from 25% to nearly 90%, depending on the strain and speed of medical response. The infection spreads through direct contact with infected bodily fluids and can rapidly lead to severe bleeding, organ failure, and multi-organ complications.

Indian health authorities, while maintaining that the immediate risk to the country remains low, have nevertheless intensified precautionary measures. Officials said screening, surveillance, quarantine preparedness, and case-management protocols were being reviewed in coordination with agencies including the National Centre for Disease Control, the Integrated Disease Surveillance Programme, and the Indian Council of Medical Research.

Laboratory preparedness is also being strengthened, with the National Institute of Virology designated for Ebola testing if required. Authorities are additionally monitoring international travellers arriving from affected African regions and reviewing isolation and quarantine arrangements at major airports and ports.

The outbreak comes at a time when global public health systems are simultaneously confronting multiple emerging infectious threats, including hantavirus incidents linked to international cruise ships and growing concerns over zoonotic diseases associated with climate change, ecological disruption, and increased human mobility.

Salim S. Abdool Karim, Director of CAPRISA and Special Advisor on pandemics to the WHO Director-General, said the delayed detection of the outbreak had added to concerns.

“This outbreak is concerning, particularly as the virus spread for weeks before being identified. The high death rate among suspected cases, including medical personnel, highlights the urgency in the outbreak response. Identifying each and every case through rapid diagnostics, surveillance, and coordinated regional action will be essential to containing this outbreak,” he said.

Experts associated with the Global Virus Network (GVN) noted that although Ebola does not spread through the air like influenza or SARS-CoV-2, outbreaks can escalate rapidly through direct exposure to infected bodily fluids, contaminated materials, or unsafe caregiving and burial practices, particularly where healthcare systems are overstretched.

“This outbreak is also a reminder that epidemic preparedness cannot focus only on the pathogens we know best,” Prof. Abdool Karim added. “Building a global network of experts ready to deal with any viral threat is critical for future epidemic responses.”